Another month in the books, and as so often I'm taking a moment to reflect on a busy September with lots of activity in the women's health innovation ecosystem. People came back from summer hibernation with what seemed like a vengeance and we saw over $250M deployed across women's health, spanning everything from menopause and maternal health to innovative diagnostics and infrastructure plays.
Three companies raised $50M+ rounds, while a cluster of family tech investments addressed caregiver support, and AI-enabled screening continued its momentum.
Notable deals included Midi Health's $50M Series C, Diana Health's $55M Series C, and Conceivable Life Sciences' $50M Series A. Beyond venture funding, we saw also significant grant activity and two strategic acquisitions: Remedy Meds' $500M acquisition of Thirty Madison and Zepp Health's purchase of Wild.AI assets.
The breadth of activity, from BoobyBiome's breast milk microbiome preservation to Lapee's public urinals for women, shows yet again the diversity of both the problems being addressed and how they're being solved.
The $50M+ Rounds: Proof Points for Scaled Models
Three companies secured $50M+ rounds this month - Midi Health ($50M Series C), Conceivable Life Sciences ($50M Series A), and Diana Health ($55M Series C). These substantial investments signal that investors are backing proven care models that can scale. Midi Health and Diana Health have demonstrated that virtual-first menopause care and hospital-partnered women's health networks, respectively, can work at scale. Conceivable's Series A, as an earlier-stage deal for automated IVF labs, suggests appetite for infrastructure plays that could fundamentally transform (fertility) care delivery.
Famtech Emerges: Addressing the Caregiver Crisis
We've also seen a notable funding cluster around famtech - companies tackling family and caregiver support. Mamaya Health ($3M) and Parento ($5.9M) address different dimensions of caregiver stress, a burden that falls disproportionately on women. This evolution moves beyond maternal health as a standalone category toward recognizing caregiving as a systemic health and economic challenge. Parento's paid parental leave insurance for small businesses is particularly noteworthy - it tackles the structural gap that leaves many families without critical support.
Rethinking Care Delivery
Companies like Lovu Health ($8M Series A) and Diana Health (which I already mentioned earlier) aren't just digitizing existing care pathways - they're building new ones. Lovu's AI-powered clinician anchored maternal health platform and Diana's hospital-partnered model suggest the sector is maturing beyond telehealth-as-access toward integrated care that could meaningfully shift outcomes. And as far as I can tell from some upcoming announcements: This new wave of companies is continuing.
AI-Enabled Screening: Following the Hype
AI-powered diagnostics unsurprisingly continue to attract capital. Prenaital ($1.57M), Fraiya (£3.5M for NHS trials), and Salient Bio (£2.35M) are all deploying AI for screening applications - prenatal conditions, pregnancy ultrasounds, and IBD diagnostics with a women's health lens. Fraiya's UK NHS trial partnership is worth watching as a potential validation pathway.
So far my analysis. What stood out to you in September?
For the full round-up of September 2025 deals, check out the article on our blog.
